Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mytogen Inc.

Division of Astellas Pharma Inc.
www.mytogen.com

Latest From Mytogen Inc.

Stem Cell Therapies: Excitement Builds but Challenges Remain

With weak pharmaceutical pipelines and demand increasing for tailored medical approaches, adult and embryonic stem cell therapies are gaining ground as a therapeutic focus. Numerous companies are now active in this research and some observers estimate that the stem cell market could reach between $8.5 and $10 billion within the next ten years.
BioPharmaceutical

ACC Highlights: Better Stents, But Are Stents Often Necessary?

The 56th Annual American College of Cardiology conference provided the expected clinical trial updates on a variety of interventional devices. But the most anticipated and surprising news of the meeting came from the COURAGE study, whose results broke against the tide of using interventional procedures and stents as primary therapy for stable coronary artery disease.
BioPharmaceutical Medical Device

Succeeding in Heart Failure, Incrementally

Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Astellas Pharma Inc.
  • Senior Management
  • Jonathan Dinsmore, PhD, Pres. & CSO
  • Contact Info
  • Mytogen Inc.
    Phone: (617) 242-9100
    13th Street
    Bldg. 96
    Charlestown, MA 02129
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register